(Q38285582)

English

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

scientific article published on January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 September 2017

1 reference

Europe PubMed Central

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

1 September 2017

type 2 diabetes

0 references

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

André J Scheen

1

1 reference

Europe PubMed Central

1 September 2017

publication date

1 January 2015

1 reference

Europe PubMed Central

1 September 2017

1 reference

Europe PubMed Central

1 September 2017

75

1 reference

Europe PubMed Central

1 September 2017

1

1 reference

Europe PubMed Central

1 September 2017

33-59

1 reference

Europe PubMed Central

1 September 2017

https://scigraph.springernature.com/pub.10.1007/s40265-014-0337-y

0 references

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of canagliflozin in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tofogliflozin: first global approval

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Luseogliflozin: First Global Approval

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of dapagliflozin on cardiovascular risk factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SGLT inhibitors in management of diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal glucose reabsorption inhibitors to treat diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of SGLT2 inhibitors on cardiovascular outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin: a review of its use in type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SGLT2 inhibitors in the treatment of type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin: a review of its use in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin: a review of its use in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of type 2 diabetes: new and future developments in treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urinary tract infections in patients with diabetes treated with dapagliflozin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ipragliflozin: first global approval

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SGLT2 versus DPP4 inhibitors for type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin: first global approval

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25488697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40265-014-0337-Y

1 reference

Europe PubMed Central

1 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

1 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38285582&oldid=2143631433"